Ayahuasca, DMT, and Mental Health: A Current Review of Scientific Studies
Dráulio B. Araújo, Lucas O. Maia, Tiago Arruda-Sanchez, Nicole Leite Galvão-Coelho, Fernanda Palhano-Fontes
Current Addiction Reports February 21, 2026 DOI: 10.1007/s40429-026-00721-7 via OpenAlex
Summary
AI-generated from the abstractPreclinical and clinical evidence suggests that ayahuasca, a traditional Amazonian brew containing DMT and β-carbolines, may treat depression, anxiety, post-traumatic stress disorder, substance use, eating, and personality disorders. Preclinical studies indicate enhanced neuroplasticity, reduced inflammation, and oxidative stress. Human neuroimaging shows decreased default mode network activity, increased functional connectivity and brain entropy, suggesting a flexible neural state and modulation of pathways related to neuroplasticity, inflammation, and stress response. The evidence is mainly observational, with users reporting emotional breakthroughs, increased self-awareness, and mystical experiences tied to therapeutic outcomes. Ayahuasca appears to target core psychological and neurobiological processes across disorders but requires caution in psychotic or bipolar individuals and should be administered with support. Randomized trials are needed to confirm efficacy and safety.
Study at a glance
| Characteristics | Review Randomized Peer reviewed |
|---|---|
| Intervention | Ayahuasca |
| Topics | Ayahuasca Default mode network |
| Keywords | Psychotherapist Neuroscience Clinical psychology |
| Key finding | Ayahuasca shows promise for treating multiple mental health disorders by modulating neuroplasticity, inflammation, and stress response, but evidence is mainly observational and randomized trials are needed. |
Abstract
Summarizes preclinical and clinical evidence on ayahuasca—a traditional Amazonian brew combining N, N-Dimethyltryptamine (DMT) and β-carbolines—in treating depression, anxiety, post-traumatic stress disorder, substance use, eating, and personality disorders. Preclinical work shows enhanced neuroplasticity, reduced inflammation, and oxidative stress. Human neuroimaging reveals decreased default mode network activity, increased functional connectivity and brain entropy, indicating a flexible neural state and modulation of pathways related to neuroplasticity, inflammation, and stress response. While promising, the evidence is mainly observational. Users report emotional breakthroughs, increased self-awareness, and mystical experiences tied to therapeutic outcomes. Ayahuasca appears to target core psychological and neurobiological processes across disorders but requires caution in psychotic or bipolar individuals and should be administered with support. Randomized trials are needed to confirm efficacy and safety. In structured, culturally sensitive settings, ayahuasca/DMT may offer a novel treatment and, by integrating indigenous wisdom with modern science, deepen our understanding of healing and consciousness.